SavedAdd your journal

Journals / Endokrinolojide Diyalog Dergisi / 2013 / Cilt: 10 - Sayı: 2

Cinacalcet for the treatment of primary hyperparathyroidism

Primer hiperparatiroidi tedavisinde sinakalset kullanımı

Hüsniye BAŞER
Bekir ÇAKIR
Reyhan ERSOY
Pages
77–81
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this letter the usage of cinacalcet in PHP is reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Parathyroidectomy is the only curative management of primary hyperparatyroidism (PHP).
📊
Key Findings & Data:However there might be need for medical therapy when operation is un- successful, there are comorbid diseases which make the patient inoperable or when the patient does not want to be operated.
💡
Conclusion & Impact:In this letter the usage of cinacalcet in PHP is reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Parathyroidectomy is the only curative management of primary hyperparatyroidism (PHP). However there might be need for medical therapy when operation is un- successful, there are comorbid diseases which make the patient inoperable or when the patient does not want to be operated. Cinacalcet is a calcimimetic agent which is allosteric modulator of Ca sensing receptor (CaSR). Ca sensing receptors are localized on the surface of parathyroid cells and play a primary role in regulation of parathormone synthesis. Cinacalcet increases the sensitivity of CaSR for extracellular Ca concentration and decreases PTH secretion. In this letter the usage of cinacalcet in PHP is reviewed.

Özet

Paratiroidektomi Primer Hiperparatiroidi (PHP) için tek küratif tedavi seçeneğidir. Bununla birlikte tekrarlanan başarısız paratiroidektomi, cerrahi öncesinde ek hastalıkların varlığı nedeniyle cerrahinin yapılamadığı ya da hastanın cerrahiyi kabul etmediği durumlarda medikal tedaviye ihtiyaç duyulabilir. Bir kalsimimetik olan Sinakalset kalsiyum duyarlı reseptör (CaSR)ün allosterik modülatörüdür. CaSRler paratiroid hücrelerin yüzeyinde lokalizedir ve PTH sekresyonun düzenlenmesinde primer rol alırlar. Sinakalset ekstrasellüler Ca konsantrasyonuna CaSR duyarlılığını artırır ve PTH sekresyonunu azaltır. Bu derlemede PHPde Sinakalset kullanımı ile ilgili literatür gözden geçirilmiştir.

🔖

Cite This Article

BAŞER, H., ÇAKIR, B., ERSOY, R. (2022). Cinacalcet for the treatment of primary hyperparathyroidism. Endokrinolojide Diyalog Dergisi, Cilt: 10 - Sayı: 2, 77–81. https://ajindex.com/articles/500701

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asympto- matic primary hyperparathyroidism: proceeding of the third international workshop. J Clin Endocrinol Metab 2009; 94: 340-350
  2. Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145-158
  3. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and mangement of primary hyper- parathyroidism. Endocr Pract 2005; 11: 49-54
  4. Elaraj DM, Clark OH. Current status and treatment of primary hyperparathyroidism. Permanente J 2008; 12: 32-37
  5. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93: 3462-3470
  6. Silverberg SJ, Shane E, Jacops TP, Bilezikian JP, Siris E. A 10- year prospective study of primary hyperparathyroisim with or without parathyroid surgery. N Eng J Med 1999; 341: 1249-1255
  7. Hatfield E, Turner J. Hypercalcaemia and primary hyper- parathyroidism. Medicine 2005; 33: 52-54
  8. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hy- perparathyroidism: new concepts in clinical, desitometric and biochemical features. J Intern Med 2005; 257: 6-17
  9. Vestergaard P. Current pharmacological options for the man- agement of primary hyperparathyroidism. Drugs 2006; 66: 2189-2211
  10. Silverberg SJ,Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathy- roidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94: 351-365
  11. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002; 17: 87-94
  12. Hagström E, Lundgren E, Mallmin H, Rastad J, Hellman P. Positive effect of parathyroidectomy on bone mineral density in mild asemptomatic primary hyperparathyroidism. J Intern Med 2006; 259: 191-198
  13. Boggs JE, Irvin 3rd GL, Carneiro DM, Molinari AS. The evolu- tion of parathyroidectomy failures. Surgery 1999; 126: 998- 1002
  14. Hedback G, Oden A. Recurrence of hyperparathyroidism: a long term follow up after surgery for primary hyperparathyroidism. Eur J Endocrinol 2003; 148: 413-421
  15. Bilezikian JP, Pott Jr JT, Fuleihan Gel- H, et al. Summary statement from a workshop on asymptomatic primary hyperparathy- roidism: a perspective for the 21st centrury. J Clin Endocrinol Metab 2002; 87: 5353-5361
  16. Nemeth EF, Heaton WH, Miller M, et al. Pharmac